Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)
- 1 February 1997
- journal article
- clinical trial
- Published by Elsevier BV in European Neuropsychopharmacology
- Vol. 7 (1), 9-24
- https://doi.org/10.1016/s0924-977x(96)00039-9
Abstract
No abstract availableThis publication has 80 references indexed in Scilit:
- Positron emission tomography and magnetic resonance imaging: A review and a local circuit neurons hypo(dys)function hypothesis of schizophreniaBiological Psychiatry, 1991
- Importance of pharmacologic control in PET studies: Effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophreniaPsychiatry Research: Neuroimaging, 1991
- Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission TomographyThe British Journal of Psychiatry, 1990
- Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patientsBiological Psychiatry, 1987
- Patterns of metabolic activity in the treatment of schizophreniaAnnals of Neurology, 1984
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartateBritish Journal of Pharmacology, 1983
- Cerebral Glucography With Positron TomographyArchives of General Psychiatry, 1982
- "Psychedelic" Experiences in Acute PsychosesArchives of General Psychiatry, 1966
- Observations on the psychotomimetic effects of sernylComprehensive Psychiatry, 1961
- Observations on the Action of Sernyl — A New Psychotropic DrugCanadian Psychiatric Association Journal, 1961